retatrutide ly3437943 phase 2 trial obesity nejm 2023 Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide (LY3437943): Mechanism of Action

And that is quite unpleasant

"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 19902015: a systematic analysis for the Global Burden of Disease Study 2015"

GLP-1 and bone health in women Rapid weight loss can affect bone density, which is particularly important for women who already face a higher osteoporosis risk, especially after menopause

Growth hormone-stimulating peptides like CJC-1295/Ipamorelin and Tesamorelin work through the bodys own GH axis to drive protein synthesis, reduce fat, and support the structural repair that makes consistent training possible

What are the adverse reactions